Click here to close now.

SYS-CON MEDIA Authors: AppDynamics Blog, Ian Goldsmith, Ed Featherston, Elizabeth White, Pat Romanski

News Feed Item

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

LONDON, April 8, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Diabetic Macular Edema Global Clinical Trials Review, H2, 2013


Diabetic Macular Edema Global Clinical Trials Review, H2, 2013

Summary

GlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Macular Edema clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Macular Edema . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Macular Edema . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Diabetic Macular Edema 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by BRIC Nations 15
Clinical Trials by G7 Nations 16
Clinical Trials in G7 Nations by Trial Status 17
Clinical Trials by E7 Nations 18
Clinical Trials in E7 Nations by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Unaccomplished Trials of Diabetic Macular Edema 23
Subjects Recruited Over a Period of Time 27
Prominent Sponsors 28
Top Companies Participating in Diabetic Macular Edema Therapeutics Clinical Trials 30
Prominent Drug Comparison 32
Clinical Trial Profiles 33
Clinical Trial Overview of Top Companies 33
Allergan, Inc. 33
Clinical Trial Overview of Allergan, Inc. 33
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
F. Hoffmann-La Roche Ltd. 37
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37
Regeneron Pharmaceuticals, Inc. 38
Clinical Trial Overview of Regeneron Pharmaceuticals, Inc. 38
Pfizer Inc. 39
Clinical Trial Overview of Pfizer Inc. 39
Bayer AG 40
Clinical Trial Overview of Bayer AG 40
Alimera Sciences, Inc. 41
Clinical Trial Overview of Alimera Sciences, Inc. 41
Santen Pharmaceutical Co., Ltd. 42
Clinical Trial Overview of Santen Pharmaceutical Co., Ltd. 42
Bausch & Lomb Incorporated 43
Clinical Trial Overview of Bausch & Lomb Incorporated 43
Clinical Trial Overview of Top Institutes / Government 44
Diabetic Retinopathy Clinical Research Network 44
Clinical Trial Overview of Diabetic Retinopathy Clinical Research Network 44
National Eye Institute 45
Clinical Trial Overview of National Eye Institute 45
Johns Hopkins University 46
Clinical Trial Overview of Johns Hopkins University 46
Shahid Beheshti University of Medical Sciences 47
Clinical Trial Overview of Shahid Beheshti University of Medical Sciences 47
The University of Sydney 48
Clinical Trial Overview of The University of Sydney 48
Moorfields Eye Hospital NHS Foundation Trust 49
Clinical Trial Overview of Moorfields Eye Hospital NHS Foundation Trust 49
Medical University of Vienna 50
Clinical Trial Overview of Medical University of Vienna 50
Hong Kong Eye Hospital 51
Clinical Trial Overview of Hong Kong Eye Hospital 51
Federal University of Sao Paulo 52
Clinical Trial Overview of Federal University of Sao Paulo 52
University of Sao Paulo 53
Clinical Trial Overview of University of Sao Paulo 53
Five Key Clinical Profiles 54
Appendix 154
Abbreviations 154
Definitions 154
Research Methodology 155
Secondary Research 155
About GlobalData 155
Contact Us 155
Disclaimer 156
Source 156



List of Tables

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone, 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries, 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries, 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries, 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries, 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries, 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries, 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase, 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Market, Global, Suspended Clinical Trials, 2013* 23
Diabetic Macular Edema Therapeutics Market, Global, Withdrawn Clinical Trials, 2013* 24
Diabetic Macular Edema Therapeutics Market, Global, Terminated Clinical Trials, 2013* 25
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 29
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 31
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Allergan, Inc., 2013* 33
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2013* 35
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2013* 37
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Regeneron Pharmaceuticals, Inc., 2013* 38
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2013* 39
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2013* 40
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Alimera Sciences, Inc., 2013* 41
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Santen Pharmaceutical Co., Ltd., 2013* 42
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Bausch & Lomb Incorporated, 2013* 43
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Diabetic Retinopathy Clinical Research Network, 2013* 44
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by National Eye Institute, 2013* 45
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2013* 46
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Shahid Beheshti University of Medical Sciences, 2013* 47
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Sydney, 2013* 48
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Moorfields Eye Hospital NHS Foundation Trust, 2013* 49
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2013* 50
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Hong Kong Eye Hospital, 2013* 51
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by Federal University of Sao Paulo, 2013* 52
Diabetic Macular Edema Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2013* 53



List of Figures

Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Zone (%), 2013* 7
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Top Countries, 2013* 8
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2013* 9
Diabetic Macular Edema Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2013* 10
Diabetic Macular Edema Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2013* 11
Diabetic Macular Edema Therapeutics Clinical Trials, North America, Top Countries (%), 2013* 12
Diabetic Macular Edema Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2013* 13
Diabetic Macular Edema Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2013* 14
Diabetic Macular Edema Therapeutics Clinical Trials, BRIC Countries (%), 2013* 15
Diabetic Macular Edema Therapeutics Clinical Trials, G7 Countries (%), 2013* 16
Diabetic Macular Edema Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2013* 17
Diabetic Macular Edema Therapeutics Clinical Trials, E7 Countries (%), 2013* 18
Diabetic Macular Edema Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2013* 19
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Phase (%), 2013* 20
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2013* 21
Diabetic Macular Edema Therapeutics Market, Global, Clinical Trials by Trial Status, 2013* 22
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2007-2012 27
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Key Sponsors, 2013* 28
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Top Companies by Phase, 2013* 30
Diabetic Macular Edema Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2013* 32
GlobalData Methodology 155


Read the full report:
Diabetic Macular Edema Global Clinical Trials Review, H2, 2013
http://www.reportbuyer.com/pharma_healthcare/treatments/diabetic_macular...

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his session at DevOps Summit, Andrei Yurkevich, CTO at Altoros, provided an overview of all the benefits and opportunities, as well as drawbacks of deploying Cloud Foundry PaaS with Juju and compared it to BOSH. Discover the features that overlap, and understand what Juju Charm is, what it is not, where you use one or the other or where you use both BOSH and Juju Charms together. Andrei Yurkevich is Cloud Foundry protagonist and CTO at Altoros. Under his supervision, the Altoros engineering ...
MeriTalk, a public-private partnership focused on improving the outcomes of government IT, today announced the results of its new report, "The Agile Advantage: Can DevOps Move Cloud to the Fast Lane?" The study, underwritten by Accenture Federal Services, reveals that approximately two-thirds of Feds say DevOps will help agencies shift into the cloud fast lane - improving IT collaboration and migration speed. But help is needed, with 66 percent saying that their agency needs to move IT services ...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water,...
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrateg...
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of present...
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific approach to user experience design that combines approaches from interaction design, industrial design and service design to create experiences that go beyond simple connected gadgets to create lasting, multi-device exp...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impac...
The 4th International Internet of @ThingsExpo, co-located with the 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - announces that its Call for Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of...
There is little doubt that Big Data solutions will have an increasing role in the Enterprise IT mainstream over time. 8th International Big Data Expo, co-located with 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - has announced its Call for Papers is open. As advanced data storage, access and analytics technologies aimed at handling high-volume and/or fast moving data all move center stage, aided by the cloud computing bo...
DevOps is the hottest moving target when it comes to software development methodologies. Many people fear that this fast-paced, barrier-breaking movement will leave information security best practices in the dust. Analysts provide recommendations to security professionals using bingo-laden terms like "moving security to the left" or "get a seat at the table." What we need are real-world examples and tactics for security practitioners to be part of DevOps. In his session at DevOps Summit, Andrew...
Some developers believe that monitoring is a function of the operations team. Some operations teams firmly believe that monitoring the systems they maintain is sufficient to run the business successfully. Most of them are wrong. The complexity of today's applications have gone far and beyond the capabilities of "traditional" system-level monitoring tools and approaches and requires much broader knowledge of business and applications as a whole. The goal of DevOps is to connect all aspects of app...
Every day we read jaw-dropping stats on the explosion of data. We allocate significant resources to harness and better understand it. We build businesses around it. But we’ve only just begun. For big payoffs in Big Data, CIOs are turning to cognitive computing. Cognitive computing’s ability to securely extract insights, understand natural language, and get smarter each time it’s used is the next, logical step for Big Data.
DevOps is all about agility. However, you don't want to be on a high-speed bus to nowhere. The right DevOps approach controls velocity with a tight feedback loop that not only consists of operational data but also incorporates business context. With a business context in the decision making, the right business priorities are incorporated, which results in a higher value creation. In his session at DevOps Summit, Todd Rader, Solutions Architect at AppDynamics, discussed key monitoring techniques...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!